Results 151 to 160 of about 2,062,013 (251)

In vitro generation of regulatory T cells: A challenging tool for studying immune aging in humans

FEBS Open Bio, EarlyView.
In vitro induction of human regulatory T cells using standard protocols generates suppressive, Foxp3‐expressing CD4+ T cells independently of TGF‐β supplementation and donor age. Regulatory T (Treg) cells play a key role in immune tolerance and homeostasis.
Lynn Muller, Jana Bleher, Birgit Weinberger, Lourdes Rocamora‐Reverte   +3 more
wiley   +1 more source

Redefining CHI3L1: Therapeutic Opportunities at the Crossroads of Immune Suppression and Disease Progression. [PDF]

Med Res Rev
Upmanyu K, Upadhyay S, Gabr MT.
europepmc   +1 more source

Ultrafast visual detection of Streptococcus suis via HtpsC‐targeted LAMP–CRISPR–Cas12a coupled with lateral flow immunochromatography

FEBS Open Bio, EarlyView.
A rapid visual test combines DNA amplification, CRISPR–based target verification, and a lateral flow strip to detect Streptococcus suis. The assay gives results in about 45 min, reduces false‐positive interpretation, and does not require fluorescence equipment.
Liu‐xin Li, Miao Xin, Xiao‐wen Cui, Shi‐yin Yu, Fei Meng, Min Cao, Xiao‐hui Xiong, Yi‐chen Lu   +7 more
wiley   +1 more source

IL-33/IL1RL1 (ST2) signalling drives immune suppression in squamous intraepithelial hyperplasia. [PDF]

Tumour Virus Res
Zhou C, Gonzalez Cruz J, Teoh SM, Tran M, Goh D, Narayanan D, Tan X, Dang TVT, Tuong ZK, Gillinder K, Bashaw A, Wells JW, Frazer IH, Nguyen Q, Chen Y, Yu M, Chandra J.   +16 more
europepmc   +1 more source

Dactolisib outperforms Rapamycin in potentiating apoptosis induced by XPO1, Bcl‐2 and Mcl‐1 blockade in preclinical glioblastoma models

FEBS Open Bio, EarlyView.
The PAM pathway and its impact on cellular metabolism. Color‐coded key symbols represent Rapamycin (R, orange, targeting mTOR) and Dactolisib (D, green, targeting PI3K/mTOR), indicating their sites of action. Created with BioRenders.com. Glioblastoma resists therapy through interconnected survival programs.
Kai Zhao, Leonie Meyer, Madita Braun, Katharina Otte, Celine Bitter, Maite Pawlik, Hartmann Raifer, Frederik Helmprobst, Axel Pagenstecher, Hans Urban, Michael C. Burger, Michael W. Ronellenfitsch, Joachim P. Steinbach, Jarmila Jedelská, Shamim Bagheri, Behrooz H. Yousefi, Pietro Di Fazio, Markus Luster, Andreas H. Mahnken, Andreas Neubauer, Andreas Burchert, Christopher Nimsky, Jörg W. Bartsch, Tillmann Rusch   +23 more
wiley   +1 more source

Reprogramming dendritic cells to overcome tumor-mediated immune suppression. [PDF]

Front Immunol
Malik JA.
europepmc   +1 more source

Chronobiology of Cancer: How Aging Fuels Oncogenesis at the Molecular Level

Aging and Cancer, EarlyView.
This graphical abstract illustrates the key biological pathways linking aging with cancer development and progression. In the upper left, cumulative exposure to ultraviolet radiation, toxins, and reactive oxygen species (ROS) causes DNA damage and genomic instability, whereas age‐related decline in repair mechanisms, such as ATM/ATR, BER, and NER ...
Anu Singh, Aroonima Misra, Sufian Zaheer
wiley   +1 more source

Roles of lactate and lactylation in tumor immune suppression and drug resistance. [PDF]

Front Immunol
Li J, Yang W, Xin T, Zhou Z, Liu X, Tang P, An J, Ma B, Peng F.   +8 more
europepmc   +1 more source

Ofatumumab in Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease: A Comparison With Rituximab

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To evaluate the efficacy and safety of ofatumumab in patients with myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD), and compare it with rituximab. Methods We conducted a single–center, observational study including 22 MOGAD patients treated with ofatumumab and 21 treated with rituximab.
Yuxin Fan, Lei Zhou, Jingzi ZhangBao, Hongmei Tan, Zhouzhou Wang, Chao Quan   +5 more
wiley   +1 more source

Regulatory T cells in the bladder cancer tumor microenvironment: mechanisms of immune suppression and therapeutic opportunities. [PDF]

Front Mol Biosci
Fukiage Y, Okubo N, Taga M, Sato Y, Terada N.   +4 more
europepmc   +1 more source